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Objective: The antifibrinolytic drug aprotinin has been the most widely used agent to
reduce bleeding and its complications in cardiac surgery. Several randomized trials
and meta-analyses have demonstrated it to be effective and safe. However, 2 recent
reports from a single database have implicated the use of aprotinin as a risk for post-
operative complications and reduced long-term survival.
Methods: In this single-institution observational study involving 7836 consecutive
patients (1998–2006), we assessed the safety of using aprotinin in risk reduction strat-
egy for postoperative bleeding.
Results: Aprotinin was used in 44% of patients. Multivariate analysis identified
aprotinin use in risk reduction for reoperation for bleeding (odds ratio, 0.51; 95% con-
fidence interval, 0.36–0.72; P5 .001) and need for blood transfusion postoperatively
(odds ratio, 0.67; 95% confidence interval, 0.57–0.79; P 5 .0002). The use of apro-
tinin did not affect in-hospital mortality (odds ratio, 1.03; 95% confidence interval,
0.71–1.49; P5 0.73), intermediate-term survival (median follow-up, 3.4 years; range,
0–8.9 years; hazard ratio, 1.09; 95% confidence interval, 0.93–1.28; P 5 .30), inci-
dence of postoperative hemodialysis (odds ratio, 1.16; 95% confidence interval,
0.73–1.85; P 5 .49), and incidence of postoperative renal dysfunction (odds ratio,
0.78; 95% confidence interval, 0.59–1.03; P 5 .07).
Conclusion: This study demonstrates that aprotinin is effective in reducing bleeding
after cardiac surgery, is safe, and does not affect short- or medium-term survival.
E
xcessive postoperative bleeding during cardiac surgery occurs in 3.6% of
patients undergoing coronary artery bypass grafting (CABG) and increases
to 11% in those requiring more complex operations. Reoperation for bleeding
increases hospital mortality 3- to 4-fold, substantially increases postoperative hospital
stay, and has a sizeable effect on health care costs.1,2 Even without the requirement for
reoperation, blood loss frequently leads to transfusion of allogeneic blood products,
which exposes patients to the risk of transfusion-related adverse effects, including
allergic reactions, transfusion errors, and blood-borne infections. Concerns about
transfusion safety, particularly in the United Kingdom, where there is the potential
added risk of variant Creutzfeldt–Jakob disease, blood product shortages and increas-
ing blood bank costs have generated an increasing interest in adopting risk-reducing
strategies for postoperative bleeding. In this context the most effective and widely
From the Departments of Cardiothoracic
Surgerya and Clinical Biochemistry,d Uni-
versity Hospital Birmingham, Birmingham,
United Kingdom; the Health Care Evalua-
tion Group,b University of Birmingham,
Birmingham, United Kingdom; NHS Health
and Social Services Information Centre,c
Leeds, United Kingdom; and the National
Institute for Clinical Outcomes Research,e
University College London, London, United
Kingdom.
Neil Howell and Domenico Pagano report
lecture fees from Bayer.
Received for publication July 20, 2007;
revisions received Oct 16, 2007; accepted
for publication Nov 8, 2007.
Address for reprints: D. Pagano,MD, FRCS,
Department Cardiothoracic Surgery, Uni-
versity Hospital Birmingham, Edgbaston,
Birmingham B15 2TH, United Kingdom
(E-mail: domenico.pagano@uhb.nhs.uk).
J Thorac Cardiovasc Surg 2008;135:495-502
0022-5223/$34.00
Copyright  2008 by The American Asso-
ciation for Thoracic Surgery
doi:10.1016/j.jtcvs.2007.11.045
Surgery for
Acquired
Cardiovascular
DiseaseThe Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 3 495
Surgery for Acquired Cardiovascular Disease Pagano et al
A
CDAbbreviations and Acronyms
CABG 5 coronary artery bypass grafting
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GFR 5 glomerular filtration rate
KIU 5 kallikrein inhibitor units
used prophylactic pharmacologic agent for reducing postop-
erative bleeding and bleeding complications is the antifibri-
nolytic drug aprotinin.3,4
The efficacy and safety of this drug have been reported in
several systematic reviews of randomized trials,3,5,6 but data
on midterm outcomes of patients treated with aprotinin are
not widely available. Two recently published and highly pub-
licized reports from a single database7,8 have implicated the
use of aprotinin in increased short- and long-term adverse out-
comes for patients undergoing cardiac surgery. This has led to
a wave of adverse publicity in North America and Europe,
which is threatening to alter risk reduction strategies widely
used in cardiac surgery and has prompted regulatory authori-
ties to review the safety of this drug.
The aim of our study was to review the effects and the
safety of aprotinin with regard to short-term and midterm
outcomes from our unit and to interpret the results in the
context of the previously published reports.
Materials and Methods
Patient Population
We reviewed data from the cardiac surgical database, which holds
prospectively collected clinical information on all patients undergo-
ing cardiac surgery at our unit. The data are acquired prospectively
as part of the patients’ pathways and are based on the minimal data-
set defined by the Society for Cardiothoracic Surgery in Great Brit-
ain and Ireland2 with some customized additions. For the purpose of
this study, we excluded patients undergoing operations requiring496 The Journal of Thoracic and Cardiovascular Surgery c Macirculatory arrest, distal aortic surgery, transplantation, surgical
intervention for thoracic trauma, and adult congenital surgery.
Data Completion
We analyzed data from January 1, 1998, to December 12, 2006. Data
on aprotinin use were available on 7836 (98%) of the 7997 eligible
patients, and this constitutes the population for this study (Figure 1).
Data on blood product transfusion requirements were available on
7693 (98.2%) of the 7836 patients, data for need of new postopera-
tive hemodialysis requirement were available on 7703 (98.3%) of
7836 patients, and preoperative and postoperative complete renal
function data were available on 7503 (95.8%) of 7836 patients.
Study End Points
In-hospital mortality was tracked from our database, and postdi-
scharge survival data were obtained from the National Central
Cardiac Audit Database, which is linked to the Office of National
Statistics (census date, January 12, 2006). In-hospital mortality
was defined as death within 30 days from the operation or at any
time within the same hospital admission. To enable comparison
with the Mangano reports, renal dysfunction was defined as a
postoperative serum creatinine level of 177 mmol/L with an increase
over the preoperative baseline level of at least 62 mmol/L.7
Percentage change in serum creatinine (%DCr) level was calculated
as follows: ð½Highest postoperative creatinine=½Preoperative
creatinine21Þ3100%. The glomerular filtration rate (GFR) was
estimated by using the Cockroft–Gault formula9 and adjusted for
each 1.73 m2 of body surface area. Percentage decrease in GFR was
calculated by using the following formula: ð½Lowest postoperative
GFR=½Preoperative GFR21Þ3100%. Data on blood product trans-
fusion is expressed as the number of patients requiring at least 1 unit of
blood product. Aprotinin was administered as one million kallikrein
inhibitor units (KIU) in the cardiopulmonary bypass reservoir, 2 mil-
lion KIU to the patient as a loading dose, and a half million KIU/h to
the patient until return to Intensive Therapy Unit (full-dose regimen).
In our institution the use of aprotinin was mainly based on sur-
geon choice and reserved for ‘‘high-risk’’ patients from 1997
through 2001. From 2002, this drug was used in an increasing num-
bers of patients, irrespective of their risk. Data are described for theFigure 1. Flow chart of the study population.
CABG, Coronary artery bypass grafting.rch 2008
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CABG was done.
Statistical Analysis
Descriptive data are expressed as the mean 6 1 standard deviation.
The level of statistical significance (a) was set at .05 (two-sided).
The risk profile in cardiac surgery is commonly assessed by
using the EuroSCORE, which contains variables known to influence
outcomes like age, sex, and ventricular function.10 We developed
prognostic models to examine whether there was an additional effect
of aprotinin on the incidence of postoperative renal dysfunction,
need for new hemodialysis, all-cause in-hospital mortality, and post-
discharge survival. In these models we included the EuroSCORE
value as a patient-level covariate, year of operation, diabetes, and
surgeon as a random effect. For the end point of renal dysfunction
and renal dialysis, we added the preoperative GFR as a patient-level
covariate in the model, a known predictor of outcome even when
mildly deranged.11 The EuroSCORE was log transformed (log
Euroscore) because this achieved a substantial improvement in
model fit, as judged by using the Aikeke information criterion.
Categorical models were conducted with PROC NLMIXED in
SAS 9.1 (SAS Institute, Cary, NC). Time-to-event analyses were
conducted by using approximate frailty models in the statistical
package R.12
Results
Summary patient demographics, type of operation per-
formed, and use of aprotinin is illustrated in Tables 1 and 2
and Figure 1. Aprotinin was used in 44.4% (3481/7836) of
patients. Patients receiving aprotinin had a higher risk profile,
including more severe heart failure; a higher prevalence of
type II diabetes, hypertension, and peripheral vascular dis-
ease; and a higher EuroSCORE (Table 1). In addition, apro-
tinin patients were also more likely to undergo more complex
operations (Table 1).
The overall in-hospital mortality was 3.7% (299/7836).
The incidence of reoperation for bleeding was 4.9% (385/
7836), and the use of aprotinin was associated with a signifi-
cant risk reduction for this end point (odds ratio, 0.51; 95%
confidence interval [CI], 0.36–0.72; P 5 .001; Table 3).
Patients requiring reoperation for bleeding had a signifi-
cantly longer postoperative hospital stay (16 6 17 vs 11 6
11 days, P , .0001). Transfusion of blood products was
required in 43% (3737/7693) of patients.
In the multivariate analysis the use of aprotinin was asso-
ciated with a reduction for transfusion requirements (odds
ratio, 0.67; 95% CI, 0.57–0.79; P 5 .0002).
Aprotinin and Survival
In-hospital mortality was 4.0% (139/3481) for the aprotinin
group and 3.5% (154/4355) for the nonaprotinin group.
The preoperative log EuroSCORE was the strongest pre-
dictor of in-hospital mortality, whereas the use of aprotinin
was not associated with an increased risk for this end point
(odds ratio, 1.03; 95% CI, 0.71–1.49; P 5 .85; Table 4).The Journal of ThorThe lack of effect of aprotinin on in-hospital survival was
independent of the preoperative EuroSCORE or the type of
operation (Figure 2, A). Postdischarge survival data were
available on 100% discharged patients. The median follow-
up time was 3.4 years (0–8.9 years). The 5-year unadjusted
survival was 85.2% for the nonaprotinin group and 80.8%
for the aprotinin group, a difference that was highly statisti-
cally significant (P , .0001). However, the preoperative
log EuroSCORE was the strongest independent predictor of
TABLE 1. Demographics in patients treated with and
without aprotinin
No aprotinin
(n 5 4355)
Aprotinin
(n 5 3481) P value
Age (y) 63.8 6 9.8 64.8 6 11 ,.0001
Female sex 1058 (24.3) 78 (28.1) .0005
CCS class
I 633 (14.5) 59 (27.6) .0001
II 1422 (32.7) 123 (32.3)
III 1037 (23.8) 821 (23.6)
IV 1263 (29.0) 573 (16.5)
NYHA class
I 1387 (31.9) 825 (23.8) ,.0001
II 1864 (42.8) 1533 (44.1)
III 832 (19.1) 799 (23.0)
IV 271 (6.2) 316 (9.1)
Diabetes
Type I 284 (6.5) 219 (6.3) ,.0001
Type II (oral
therapy)
351 (8.1) 407 (11.7)
Type II (diet) 153 (3.5) 124 (3.6)
Hypertension 2401 (55.1) 2204 (63.3) ,.0001
Peripheral vascular
disease
446 (10.2) 432 (12.4) .003
LV function
Good (EF .50%) 2754 (63.2) 2161 (62.1) .071
Moderate (EF
30%–49%)
1281 (29.4) 1098 (31.5)
Poor (EF ,30%) 315 (7.2) 216 (6.2)
Previous MI 1957 (44.9) 1127 (32.3) ,.0001
EUROScore 3.8 6 2.8 5 6 3.4 ,.0001
Urgent/emergency
procedure
1507 (34.6) 1120 (32.1) ,.0001
Procedure
CABG only 3421 (78.6) 1982 (56.9) ,.0001
Valve only 532 (12.2) 817 (23.5)
CABG 1 valve 314 (7.2) 456 (13.1)
Valve 1 other 16 (0.4) 103 (3)
CABG 1 other 66 (1.5) 74 (2.1)
Other cardiac
surgery
6 (0.1) 49 (1.4)
Values shown in parentheses are percentages. CCS, Canadian Cardiovas-
cular Society; NYHA, New York Heart Association (5 missing data for the
aprotinin group); LV, left ventricle (5 not measured in the no Aprotinin group
and 6 not measured in the aprotinin group); EF, ejection fraction.acic and Cardiovascular Surgery c Volume 135, Number 3 497
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No aprotinin (n 5 4355) Aprotinin (n 5 3481) P value
CABG only
EUROScore (mean 6 SD) 3.2 6 2.5 3.6 6 2.7 ,.0001
Priority (no. of patients)
Elective 2196 (64.8) 1296 (67.5) .19
Urgent 1159 (34.2) 602 (31.3)
Emergency 36 (1) 23 (1.2)
Triple-vessel disease (no. of patients) 2676 (78.9) 1559 (81.2) .05
LMS (no patients) 653 (19.3) 560 (29.2) ,.0001
No. of CABG (mean 6 SD) 2.8 6 0.8 3.0 6 0.9 .001
Clamp time (mean min 6 SD) 45 6 20 52 6 21 ,.0001
Bypass time (mean min 6 SD) 80 6 31 91 6 33 ,.0001
LCOS (no. of patients) 1183 (34.9) 571 (29.7) ,.0001
Reoperation (no. of patients) 176 (5.3) 56 (2.9) ,.0001
In-hospital mortality (no. of patients) 94 (2.8) 35 (1.8) .18
Other cardiac surgery
EUROScore (mean 6 SD) 6.0 6 2.7 6.8 6 3.3 ,.0001
Priority (no. of patients)
Elective 649 (67.3) 1061 (68) .001
Urgent 298 (30.9) 430 (27.6)
Emergency 17 (1.8) 69 (4.4)
Triple-vessel disease (no. of patients) 218 (22.7) 335 (21.5) .052
LMS (no. of patients) 52 (5.4) 126 (8.1) .001
No. of distals (no. of patients) 0.9 6 1.2 0.9 6 1.3 .91
Clamp time (mean min 6 SD) 75 6 33 91 6 42 ,.0001
Bypass time (mean min 6 SD) 103 6 46 128 6 56 ,.0001
LCOS (no. of patients) 449 (46.5) 770 (49.4) .4
Reoperation (no. of patients) 73 (7.7) 80 (5.2) ,.0001
In-hospital mortality (no. of patients) 58 (6) 102 (6.5) .779
Values in parentheses are percentages. CABG, Coronary artery bypass grafting; SD, standard deviation; LMS, left main stem; LCOS, low cardiac output
syndrome (combined end point of use of inotropic agents, intra-operative balloon pump, or both).long-term survival (hazard ratio, 3.51; 95% CI, 3.12–3.93;
P , .0001). The use of aprotinin was not associated with
reduced survival when accounting for log EuroSCORE,
year of operation, diabetes, and surgeon as a random effect
(hazard ratio, 1.09; 95% CI, 0.93–1.28; P 5 .30, Table 5).
The lack of influence of aprotinin on long-term survival
was independent of the preoperative EuroSCORE or the
type of operation (Figure 2, B).
Aprotinin and Renal Function
Detailed renal function data were available on 96% (3349/
3481) of patients in the aprotinin group and 95% (4154/
4355) in the nonaprotinin group. The overall incidence of
new postoperative hemodialysis was 2.4% (186/7703).
Hemodialysis was required in 1.5% (81/5238) of the patients
undergoing CABG and in 4.3% (105/2465) of the patients
undergoing other cardiac operations. The incidence of new
hemodialysis in patients undergoing CABG was 1.7% (33/
1912) for the aprotinin group and 1.4% (48/3326) for the
nonaprotinin group, and that for patients undergoing other
cardiac surgery was 4.9% (75/1526) in the aprotinin group
and 3.2% (30/939) in the nonaprotinin group.498 The Journal of Thoracic and Cardiovascular Surgery c MaIn the multivariate analysis the use of aprotinin was not
associated with an increased risk of requiring postopera-
tive hemodialysis (odds ratio, 1.16; 95% CI, 0.73–1.85;
P 5 .49).
TABLE 3. Multivariate analysis of risk factors for
reoperation for bleeding
Odds ratio 95% CI P value
Log EuroSCORE 1.71 1.40–2.10 .0001
Diabetes 0.76 0.55–1.04 .0832
Year of operation
1998 0.35 0.19–0.67 .0041
1999 0.85 0.49–1.47 .5344
2000 1.00 0.58–1.71 .9986
2001 1.51 0.93–2.57 .096
2002 1.11 0.68–1.81 .6503
2003 1.08 0.66–1.77 .739
2004 1.10 0.69–1.75 .6671
2005/2006 0 0–0
Aprotinin 0.51 0.36–0.72 .0012
95% CI, 95% Confidence interval.rch 2008
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3.5% of patients receiving aprotinin and 4.9% of those not
treated with aprotinin. The use of aprotinin was not associ-
ated with an increase in this end point (odds ratio, 0.78;
95% CI, 0.59–1.03; P 5 .07). We subdivided patients in
quartiles of renal dysfunction based on the relative changes
in GFR or creatinine values after surgical intervention. Apro-
tinin had no effect on these end points (Table 6).
In the multivariate analysis the use of aprotinin had no sig-
nificant effect on serum creatinine values postoperatively
(mean change from preoperative, 3.3 mmol/L; 95% CI,
20.83 to 7.52 mmol/L; P 5 .12) or GFR postoperatively
(mean change from preoperative, 20.19 mL/min per 1.73
m2; 95% CI, 21.26 to 0.87; P 5 .72).
TABLE 4. Multivariate analysis of risk factors for
in-hospital mortality
Odds ratio 95% CI P value
Log EuroSCORE 7.36 5.46–9.94 ,.0001
Diabetes 1.49 1.08–2.04 .0184
Year of operation
1998 2.29 1.30–4.06 .0084
1999 1.91 1.06–3.45 .0348
2000 2.28 1.29–4.04 .009
2001 2.41 1.35–4.31 .0065
2002 1.67 0.95–2.93 .0714
2003 1.43 0.82–2.49 .1884
2004 1.01 0.58–1.75 .9729
2005/2006 0 0–0
Aprotinin 1.03 0.71–1.49 .851
95% CI, 95% Confidence interval.The Journal of ThorDiscussion
The role of aprotinin in cardiac surgery has been studied in 64
prospective randomized trials, and the evidence that this drug
is effective in reducing bleeding and its complications was
clearly established since the 12th trial in 1992.5,14 With
regard to the safety of aprotinin, concerns have been raised
since its phase II trials that it might be associated with
cerebral, myocardial, and renal adverse events.15 A recent
meta-analysis of 35 randomized trials including 3879
patients undergoing CABG showed no increase in the rates
of myocardial infarction, renal failure, or mortality with apro-
tinin but indicated a reduced stroke rate in the treatment
group.3 A larger systematic review of randomized studies
that included patients undergoing CABG, other cardiac sur-
gery, or both confirmed the safety of aprotinin with regard
to operative mortality, stroke, myocardial infarction, or renal
failure, but there was an increased risk of renal dysfunction in
the treatment group.6 There are no large-scale randomized
studies or meta-analyses to address the effect of aprotinin
on long-term survival.
In our study the use of aprotinin was associated with a sig-
nificant reduction in reoperation for bleeding and need for
blood transfusions. Reduction in reoperation for bleeding
has been associated with a reduction in mortality, morbidity,
and resource use,1,2 whereas blood transfusions are known to
confer immediate16 and long-term risks to the patient.17,18
Aprotinin and Survival
Midterm and long-term survival after cardiac surgery
depends onmany factors, including the patients’ preoperative
risk profiles, the type of operation, and the postoperative
complications. Aprotinin is usually administered to patients
with a higher risk profile or to those undergoing moreFigure 2. Forest plots illustrating the effects of aprotinin on in-hospital mortality (A) and long-term survival (B) for
the entire study population and for patients with low (Euroscore 0-5), medium (Euroscore 6-9), and high (Euroscore
$10) risk. Data also illustrate the effects of aprotinin on patients undergoing isolated coronary artery bypass graft-
ing (CABG) or other cardiac surgery. OR, Odds ratio; HR, hazard ratio; 95% CI, 95% confidence interval.acic and Cardiovascular Surgery c Volume 135, Number 3 499
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addressed when analyzing observational studies. The most
significant factor influencing postdischarge survival in our
study was the patients’ EuroSCOREs, which is in accordance
with previous reports.19-21 This finding is not surprising
given that the EuroSCORE is comprised of variables, such
as age, left ventricular function, pulmonary disease, and
peripheral vascular disease, which are known to influence
long-term survival. When accounting for these prognostic
indicators, the use of aprotinin had no adverse effect on
in-hospital mortality or midterm postdischarge survival in
our study. These findings were at odds with the study by
Mangano and colleagues.8 In that study aprotinin was used
in patients with a more adverse risk profile, among whom
there was a 21% greater incidence of congestive heart failure
than in the control group, 37%more pulmonary disease, 32%
more renal disease, 50% more carotid disease, and 2-fold
more concomitant valvular disease, all factors well known
to influence survival. Propensity scores were used to handle
selection bias in their observational study. However, it is
known that if the number of variables for which to match is
increased, matching is not practical. In our study, although
patients receiving aprotinin have a worse preoperative risk
profile, the overall risk spread appears more balanced (Table
1) than in the report by Mangano and colleagues.8 This is
possibly due to the fact that since 2002, there was an increas-
ing use of aprotinin in most patients, irrespective of their
preoperative risk (Figure 3). The study by Mangano and col-
leagues reports the long-term outcomes of patients undergo-
ing CABG, and our findings extend to other common cardiac
surgical operations.
Aprotinin and Renal Complications
A deterioration in postoperative renal function, particularly
when leading to hemodialysis, is associated with increased
TABLE 5. Multivariate analysis of risk factors for medium-
term survival
Hazard ratio 95% CI P value
Log EuroSCORE 3.51 3.12–3.93 ,.0001
Diabetes 1.22 1.05–1.42 .008
Year of operation
1998 1.58 1.17–2.13 .0031
1999 1.50 1.11–2.03 .008
2000 1.37 1.00–1.86 .048
2001 1.46 1.06–2.00 .02
2002 1.29 0.95–1.74 .10
2003 1.17 0.86–1.58 .33
2004 0.93 0.68–1.27 .65
2005/2006 0.00 0–0
Aprotinin 1.09 0.93–1.28 .30
95% CI, 95% Confidence interval.500 The Journal of Thoracic and Cardiovascular Surgery c Marin-hospital mortality and a decreased postdischarge sur-
vival.13 The reported incidence of renal dysfunction after car-
diac surgery is dependent on the definition used and ranges
between 0.9% and 29%.22-24 In addition, postoperative renal
function is influenced by many preoperative and intraopera-
tive risk factors.13,25 Previous studies have suggested an asso-
ciation between the use of aprotinin and a transient increase in
postoperative serum creatinine levels.26 A meta-analysis
including only patients undergoing CABG showed no differ-
ence in the incidence of postoperative renal complications
between aprotinin and placebo.3 A recent meta-analysis that
included patients undergoing valvular heart surgery has
shown that aprotinin is associated with an increased risk for
postoperative renal dysfunction.6 In this study renal dysfunc-
tion was defined as an increase in postoperative creatinine
value of 40 mmol/L from the preoperative value. In our study
we used 2 different definitions to identify renal dysfunction:
an absolute change in postoperative creatinine value, as
reported by Mangano and colleagues,7 to allow direct com-
parison with their study and a relative change in either creat-
inine or GFR after the operation, which is known to be more
accurate in predicting outcome.27 We found that the use of
aprotininwas not associatedwith a change in serum creatinine
TABLE 6. Renal dysfunction by aprotinin group
No aprotinin
(n 5 4154)
Aprotinin
(n 5 3349) P value
Preoperative creatinine (mmol/L) 114 6 52 115 6 67 .0080
Peak Postoperative creatinine
(mmol/L)
138 6 84 140 6 93 .1166
Mean increase in creatinine
(mmol/L)
27 6 60 25 6 64 .1166
Preoperative renal impairment
(no. of patients)
78 (2.1%) 103 (3.3%) .0046
Increase in creatinine from
preoperative value
(no. of patients)
,25% 3072 2449 .32
25%–,50% 536 446
50%–,100% 296 258
$100% 251 196
Decrease in GFR from
preoperative value
(no. of patients)
,25% 3320 2640 .18
25%–,50% 577 511
50%–,75% 230 182
$75% 18 11
Renal dysfunctiony 440 359 .45
Approximately adjusted for log Euroscore, diabetes, year of operation, and
surgeon as random effects and preoperative creatinine score for postoper-
ative measures. GFR, Glomerular filtration rate. *Preoperative creatinine
$ 200 mmol/L. yAccording to definition used by Mangano and associates.13ch 2008
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CDFigure 3. Graph illustrating the percentage of
patients undergoing coronary artery bypass
grafting (CABG) and those undergoing other
cardiac operations in which aprotinin had
been used at out institution.values or in estimated GFR postoperatively. Our findings
were at odds with the report from Mangano and colleagues.7
In their study patients receiving aprotinin had a significantly
higher incidence of risk factors known to increase the risk
of renal dysfunction after surgical intervention.14 In our anal-
ysis we have attempted to adjust for factors like preoperative
EuroSCORE, GFR, age, diabetes, and year of operation.
Mangano and colleagues7 do not report data on patient age,
cardiopulmonary bypass time, and use of aspirin, factors
well known to influence postoperative renal function, as
reported by the same authors in other publications.28 In one
study byMangano and colleagues7 the incidence of renal dys-
function was 2% in the control group. This is lower than the
7.7% incidence previously reported by the same group, appar-
ently using the same database of patients, and among the low-
est reported in the literature.13 In our study, when using the
same definition as the study by Mangano and colleagues,7
renal dysfunction occurred in 4.9% of patients without apro-
tinin, and this finding is in accordance with a number of pre-
vious reports.13,22,29,30 Furthermore, the incidence of renal
dysfunction in our aprotinin group was lower than that in
the aprotinin group in the study by Mangano and colleagues
(3.5% vs 5%).7 Changes of serum creatinine values from
the preoperative value predict outcome more accurately.27
A postoperative increase in serum creatinine value of 50%
or greater from its preoperative value is clinically significant
and affects in-hospital and long-term outcome.27 When using
this threshold, the use of aprotinin was not associated with an
increase in the incidence of this end point in our study. This
was the case across all ranges of preoperative creatinine
values (data not shown).
Finally, there was no difference in the incidence of new
hemodialysis between the aprotinin and nonaprotinin groups,
and this is in accordance with all randomized studies.3,6
Study Limitations
The first limitation of our study is inherent in its observational
nature. Statistical modeling might go some way toward
accounting for differences in risk between subjects but pro-The Journal of Thovides imperfect adjustment and remains open to residual con-
founding. In a study examining the risk associated with the
use of aprotinin, it appears likely that a latent risk is described
simply by the choice of the clinician to use or not to use the
agent in subjects who appear otherwise at the same apparent
risk. The use of aprotinin in the early years of our study was
reserved for patients with a higher risk profile, which intro-
duces an inherent bias against aprotinin. The changing selec-
tion criteria for aprotinin use over time is a strength of the
study because this changing selection bias could be condi-
tioned for by including year of intervention as a patient level
factor in the analysis. Our study is based on a single-center
experience that encompasses the data from only 8 surgeons.
Although this can be seen as a potential limitation, it elimi-
nates institutional influences inherent in studies in which
data are derived from a mixture of small-volume institutions,
which might be important when nonrandomized studies are
reported.
Our dataset was not intended to study the effects of aproti-
nin, and therefore we do not have data on the incidence of
postoperative new myocardial infarction. The incidence of
low cardiac output syndrome, however, a combined end point
of use of an intra-aortic balloon pump, inotropic support, or
both, was not increased in the aprotinin group (Table 2).
In summary, with all the limitations of reporting observa-
tional studies involving an agent that is normally adminis-
tered to patients with a higher risk profile, our study
indicates that the use of aprotinin, although beneficial in
reducing the risk of bleeding and the need for blood trans-
fusion, is not associated with adverse effects on renal
function or postdischarge survival. Based on the presented
evidence, the withdrawal of aprotinin from cardiac surgeons’
risk reduction armamentarium will seriously threaten patient
safety for no perceptible gain and might cost lives.
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